AR112844A1 - PHARMACEUTICALLY STABILIZED HYALURONIC ACID-BASED HYDROGEL COMPOSITION AND PREPARATION METHOD OF THIS - Google Patents

PHARMACEUTICALLY STABILIZED HYALURONIC ACID-BASED HYDROGEL COMPOSITION AND PREPARATION METHOD OF THIS

Info

Publication number
AR112844A1
AR112844A1 ARP180102817A ARP180102817A AR112844A1 AR 112844 A1 AR112844 A1 AR 112844A1 AR P180102817 A ARP180102817 A AR P180102817A AR P180102817 A ARP180102817 A AR P180102817A AR 112844 A1 AR112844 A1 AR 112844A1
Authority
AR
Argentina
Prior art keywords
hyaluronic acid
preparation
based hydrogel
pharmaceutically stabilized
hydrogel composition
Prior art date
Application number
ARP180102817A
Other languages
Spanish (es)
Inventor
Jin A Seo
Jin Eon So
In Seok Jang
Hyun Tae Jung
Jeong A Yang
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR112844A1 publication Critical patent/AR112844A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una composición farmacéuticamente estabilizada que comprende un hidrogel a base de ácido hialurónico, un corticosteroide y un agente estabilizante, en el que el agente estabilizante incluye un estabilizante que contiene azufre. Reivindicación 16: Una preparación inyectable que comprende la composición farmacéuticamente estabilizada según una cualquiera de las reivindicaciones 1 a 15. Reivindicación 18: El método de preparación de una composición farmacéuticamente estabilizada de la reivindicación 17, en el que la etapa de esterilización de la mezcla se lleva a cabo con un autoclave.The present relates to a pharmaceutically stabilized composition comprising a hyaluronic acid-based hydrogel, a corticosteroid and a stabilizing agent, wherein the stabilizing agent includes a sulfur-containing stabilizer. Claim 16: An injectable preparation comprising the pharmaceutically stabilized composition according to any one of claims 1 to 15. Claim 18: The method of preparing a pharmaceutically stabilized composition of claim 17, wherein the step of sterilizing the mixture is carried out with an autoclave.

ARP180102817A 2017-09-29 2018-09-28 PHARMACEUTICALLY STABILIZED HYALURONIC ACID-BASED HYDROGEL COMPOSITION AND PREPARATION METHOD OF THIS AR112844A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170127756 2017-09-29

Publications (1)

Publication Number Publication Date
AR112844A1 true AR112844A1 (en) 2019-12-18

Family

ID=66164361

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102817A AR112844A1 (en) 2017-09-29 2018-09-28 PHARMACEUTICALLY STABILIZED HYALURONIC ACID-BASED HYDROGEL COMPOSITION AND PREPARATION METHOD OF THIS

Country Status (3)

Country Link
KR (1) KR20190038368A (en)
AR (1) AR112844A1 (en)
TW (1) TWI674096B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026494A1 (en) * 2019-08-07 2021-02-11 Prolynx Llc Steam sterilization of hydrogels crosslinked by beta-eliminative linkers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723458C (en) * 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
CN105026480A (en) * 2013-01-11 2015-11-04 卡比兰治疗公司 Stabilized compositions comprising hyaluronic acid

Also Published As

Publication number Publication date
KR20190038368A (en) 2019-04-08
TW201914593A (en) 2019-04-16
TWI674096B (en) 2019-10-11

Similar Documents

Publication Publication Date Title
ECSP19030002A (en) 1,2,4-TRIAZOLONES 2,4,5-TRISUSTITUIDED
NI201900085A (en) 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES
UY37201A (en) NEW DERIVATIVES OF PIRAZOLOPIRIMIDINA
AR102869A1 (en) QUICK ACTION INSULIN COMPOSITIONS
CL2020000220A1 (en) Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction.
AR103215A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES PLASMINÓGENO AND USES OF THIS
CO2017008148A2 (en) Nasal powder formulation for the treatment of hypoglycemia
DOP2019000275A (en) NEW BICYCLIC PIRAZOLE DERIVATIVES
BR112016022394A2 (en) PHARMACEUTICALLY ACCEPTABLE COMPOSITION, COMPOSITION IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE INJECTABLE SOLUTION, USE OF THE COMPOSITION, AND METHOD FOR PREPARING THE PHARMACEUTICALLY ACCEPTABLE INJECTABLE COMPOSITION
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
BR112017006406A2 (en) compositions and methods for the treatment and prophylaxis of surgical site infections
CL2019001200A1 (en) Vaccine against porcine parvovirus and porcine reproductive respiratory syndrome virus and methods of its production.
EP4233926A3 (en) Methods of manufacturing injectable gels comprising cross-linked hyaluronic acid and hydroxyapatite
ECSP20008441A (en) DIHYDROOXADIAZINONES
BR112017016483A2 (en) encapsulation of high power active agents
BR112018006870A2 (en) therapeutic nanoparticles comprising a therapeutic agent and methods for producing and using them
BR112018075221A2 (en) microparticles comprising a sulfur-containing compound
BR112017026904A2 (en) lefamulin injectable pharmaceutical formulations
AR112844A1 (en) PHARMACEUTICALLY STABILIZED HYALURONIC ACID-BASED HYDROGEL COMPOSITION AND PREPARATION METHOD OF THIS
BR112021019903A2 (en) Aqueous pharmaceutical composition, use of the aqueous pharmaceutical composition and method of producing an aqueous pharmaceutical composition
AR100618A1 (en) PREPARATION PROCEDURE FOR HUMAN ALBUMIN WITH REDUCED DISSOLVED OXYGEN LEVEL
ECSP19020167A (en) LIPOIC ACID CHOLIN ESTER COMPOSITIONS AND METHODS FOR STABILIZING IN PHARMACEUTICALLY RELEVANT PHARMACOLOGICAL PRODUCTS
AR120320A1 (en) READY-TO-USE AESTHETIC COMPOSITIONS
BR112017015613A2 (en) levodopa and carbidopa intestinal gel and methods of use
BR112017006402A2 (en) methods for treating peri-implantitis

Legal Events

Date Code Title Description
FB Suspension of granting procedure